All things point in that direction
#Zantrene (Disruptive Epigenetic Platform Therapy)
[First in class - Best in class - FTO inhibitor]
FTO Commercial Potential
Source: Investor-Presentation-November-2021.pdf (raceoncology.com)
Cancers overexpressing FTO (29+ cancers)
Source: www.raceoncology.com.au
FTO Pathways that may aid in overcoming resistance.
Source: IJMS | Free Full-Text | FTO m6A Demethylase in Obesity and Cancer: Implications and Underlying Molecular Mechanisms | HTML (mdpi.com)
Standard of Care (FTO Upregulation)
Sample treatments that upregulate FTO, which may benefit from FTO inhibition due to acquire resistance.
Dacogen (Decitabine) - Upregulate FTO
Source: Targeting FTO suppresses cancer stem cell maintenance and immune evasion - PMC (nih.gov)
Bortezomib (Bort) - Upregulate FTO
Source: FTO promoted MM progression and Bort resistance A and B qRT-PCR and... | Download Scientific Diagram (researchgate.net)
Radio Therapy - Upregulate FTO
Source: m6A demethylase FTO renders radioresistance of nasopharyngeal carcinoma via promoting OTUB1-mediated anti-ferroptosis - ScienceDirect
Not an opinion, DYOR and read the source documents for context.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.23 |
Change
0.005(0.41%) |
Mkt cap ! $218.4M | |||
| Open | High | Low | Value | Volume |
| $1.24 | $1.26 | $1.23 | $57.32K | 46.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4289 | $1.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.24 | 423 | 1 |
View Market Depth
| Last trade - 11.13am 25/06/2025 (20 minute delay) ? |
| RAC (ASX) Chart |